These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 24785428)

  • 21. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
    Dutta S; Reed RC
    J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamic and pharmacokinetic interactions of perampanel and other antiepileptic drugs in a rat amygdala kindling model.
    Wu T; Nagaya Y; Hanada T
    Seizure; 2014 Oct; 23(9):732-9. PubMed ID: 24997072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
    Ahmad A; Garnett WR
    Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perampanel: a new agent for adjunctive treatment of partial seizures.
    Faulkner MA
    Am J Health Syst Pharm; 2014 Feb; 71(3):191-8. PubMed ID: 24429011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules.
    Garnett WR; McLean AM; Zhang Y; Clausen S; Tulloch SJ
    Curr Med Res Opin; 2003; 19(6):519-25. PubMed ID: 14594524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.
    Rektor I
    Expert Opin Pharmacother; 2013 Feb; 14(2):225-35. PubMed ID: 23259931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures.
    Vazquez B; Yang H; Williams B; Zhou S; Laurenza A
    Epilepsia; 2015 Jul; 56(7):e90-4. PubMed ID: 26096637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perampanel: a novel antiepileptic for the adjunctive treatment of refractory partial onset seizures.
    Owen RT
    Drugs Today (Barc); 2013 Jan; 49(1):23-31. PubMed ID: 23362493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
    Clemens A; Haertter S; Friedman J; Brueckmann M; Stangier J; van Ryn J; Lehr T
    Curr Med Res Opin; 2012 Feb; 28(2):195-201. PubMed ID: 22208675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
    Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
    Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical course of intoxication with the new anticonvulsant drug perampanel.
    Hoppner AC; Fauser S; Kerling F
    Epileptic Disord; 2013 Sep; 15(3):362-4. PubMed ID: 24001596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
    Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
    Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The discovery and development of perampanel for the treatment of epilepsy.
    Hanada T
    Expert Opin Drug Discov; 2014 Apr; 9(4):449-58. PubMed ID: 24559052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials.
    Majid O; Laurenza A; Ferry J; Hussein Z
    Br J Clin Pharmacol; 2016 Aug; 82(2):422-30. PubMed ID: 27038098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures.
    Takenaka O; Ferry J; Saeki K; Laurenza A
    Acta Neurol Scand; 2018 Apr; 137(4):400-408. PubMed ID: 29171002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: a randomized, multicenter, open-label phase 1 study.
    Manitpisitkul P; Shalayda K; Todd M; Wang SS; Ness S; Ford L
    Epilepsia; 2013 Jan; 54(1):156-64. PubMed ID: 23157581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy.
    El Desoky ES
    Fundam Clin Pharmacol; 2014 Oct; 28(5):473-80. PubMed ID: 24750493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.
    Perucca E; Elger C; Halász P; Falcão A; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2011 Sep; 96(1-2):132-9. PubMed ID: 21680153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
    Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
    Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
    Reed RC; Dutta S; Liu W
    Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.